^
Association details:
| Biomarker: | BRAF L485W |
|---|---|
| Cancer: | Gallbladder Cancer |
| Drug: | ulixertinib (BVD-523) (ERK2 inhibitor, ERK1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
Published date:
02/01/2018
Excerpt:
Tumor response to ulixertinib was assessed in 25 and 81 evaluable patients...A patient with gallbladder adenocarcinoma with a BRAF L485W mutation who experienced partial response in two lesions (green circles) over 12 weeks.
DOI:
10.1158/2159-8290.CD-17-1119
Trial ID:
